RET and neoplasm: Clinicians may also test for Neurotrophic Receptor Tyrosine Kinase (NTRK) fusions, microsatellite instability-high/deficient mismatch repair biomarkers, tumor mutational burden, and Ret Proto-Oncogene (RET)-fusion in certain circumstances [125].